10x Genomics Statistics
Total Valuation
10x Genomics has a market cap or net worth of $2.00 billion. The enterprise value is $1.72 billion.
| Market Cap | 2.00B |
| Enterprise Value | 1.72B |
Important Dates
The next confirmed earnings date is Thursday, August 8, 2024, after market close.
| Earnings Date | Aug 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
10x Genomics has 119.71 million shares outstanding. The number of shares has increased by 3.26% in one year.
| Shares Outstanding | 119.71M |
| Shares Change (YoY) | +3.26% |
| Shares Change (QoQ) | +0.69% |
| Owned by Insiders (%) | 2.17% |
| Owned by Institutions (%) | 91.90% |
| Float | 103.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 196.08 |
| PS Ratio | 3.20 |
| Forward PS | 2.83 |
| PB Ratio | 2.78 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.75 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.22, with a Debt / Equity ratio of 0.13.
| Current Ratio | 5.22 |
| Quick Ratio | 4.26 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17,126.47 |
Financial Efficiency
Return on equity (ROE) is -35.30% and return on invested capital (ROIC) is -33.89%.
| Return on Equity (ROE) | -35.30% |
| Return on Assets (ROA) | -27.60% |
| Return on Capital (ROIC) | -33.89% |
| Revenue Per Employee | $496,782 |
| Profits Per Employee | -$209,929 |
| Employee Count | 1,259 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 2.68 |
Taxes
In the past 12 months, 10x Genomics has paid $7.39 million in taxes.
| Income Tax | 7.39M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -72.23% in the last 52 weeks. The beta is 1.84, so 10x Genomics's price volatility has been higher than the market average.
| Beta (5Y) | 1.84 |
| 52-Week Price Change | -72.23% |
| 50-Day Moving Average | 21.23 |
| 200-Day Moving Average | 36.42 |
| Relative Strength Index (RSI) | 37.76 |
| Average Volume (20 Days) | 2,363,597 |
Short Selling Information
The latest short interest is 10.68 million, so 8.92% of the outstanding shares have been sold short.
| Short Interest | 10.68M |
| Short Previous Month | 10.48M |
| Short % of Shares Out | 8.92% |
| Short % of Float | 10.30% |
| Short Ratio (days to cover) | 7.90 |
Income Statement
In the last 12 months, 10x Genomics had revenue of $625.45 million and -$264.30 million in losses. Loss per share was -$2.23.
| Revenue | 625.45M |
| Gross Profit | 403.84M |
| Operating Income | -274.84M |
| Pretax Income | -256.91M |
| Net Income | -264.30M |
| EBITDA | -210.40M |
| EBIT | -256.90M |
| Loss Per Share | -$2.23 |
Balance Sheet
The company has $371.81 million in cash and $92.18 million in debt, giving a net cash position of $279.64 million or $2.34 per share.
| Cash & Cash Equivalents | 371.81M |
| Total Debt | 92.18M |
| Net Cash | 279.64M |
| Net Cash Per Share | $2.34 |
| Equity (Book Value) | 718.83M |
| Book Value Per Share | 6.00 |
| Working Capital | 458.36M |
Cash Flow
In the last 12 months, operating cash flow was -$26.80 million and capital expenditures -$46.95 million, giving a free cash flow of -$73.75 million.
| Operating Cash Flow | -26.80M |
| Capital Expenditures | -46.95M |
| Free Cash Flow | -73.75M |
| FCF Per Share | -$0.62 |
Margins
Gross margin is 64.57%, with operating and profit margins of -43.94% and -42.26%.
| Gross Margin | 64.57% |
| Operating Margin | -43.94% |
| Pretax Margin | -41.08% |
| Profit Margin | -42.26% |
| EBITDA Margin | -33.64% |
| EBIT Margin | -41.07% |
| FCF Margin | -11.79% |
Dividends & Yields
10x Genomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.26% |
| Shareholder Yield | -3.26% |
| Earnings Yield | -13.22% |
| FCF Yield | -3.69% |
Analyst Forecast
The average price target for 10x Genomics is $34.25, which is 105.09% higher than the current price. The consensus rating is "Buy".
| Price Target | $34.25 |
| Price Target Difference | 105.09% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (5Y) | 12.76% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
10x Genomics has an Altman Z-Score of 4.19 and a Piotroski F-Score of 3.
| Altman Z-Score | 4.19 |
| Piotroski F-Score | 3 |